

## Datasheet: MCA2200D549GA

<b>Description:</b>	MOUSE ANTI C-MYC:DyLight®549
<b>Specificity:</b>	C-MYC
<b>Format:</b>	DyLight®549
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	9E10
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

### Product Details

**RRID** AB\_10843428

**Applications** This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry (1)	▪			Neat
Immunofluorescence	▪			Neat - 1/10

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems using appropriate negative/positive controls.

(1) **Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code [BUF09](#)) for this purpose.**

**Target Species** Human

**Product Form** Purified IgG conjugated to DyLight®549 - liquid

Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	DyLight®549	562	576

**Preparation** Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

**Buffer Solution** Phosphate buffered saline

**Preservative Stabilisers** 0.09% Sodium Azide (NaN<sub>3</sub>)

**Approx. Protein Concentrations** IgG concentration 1.0mg/ml

**Immunogen** Synthetic peptide sequence corresponding to the C-terminal region (residues 408-439) of human c-myc conjugated to keyhole limpet hemocyanin.

**External Database  
Links**

**UniProt:**

[P01106](#) [Related reagents](#)

**Entrez Gene:**

[4609](#) MYC [Related reagents](#)

---

**Synonyms**

BHLHE39

---

**Fusion Partners**

Spleen cells from immunised BALB/c mice were fused with cells of the SP2/0 myeloma cell line.

---

**Specificity**

**Mouse anti c-myc antibody, clone 9E10** detects the p62<sup>c-myc</sup> proto-oncogene protein, which is involved in the regulation of the cell cycle and cell growth. C-myc is primarily located to the cell nucleus, but has also been shown to localised to the cytoplasm in several cell lines ([Craig \*et al.\* 1993](#)). Overexpression of c-myc has been reported in a wide variety of human cancers ([Nesbit \*et al.\* 1999](#)).

Mouse anti c-myc antibody, clone 9E10 recognizes the sequence EQKLISEEDL and may be used to detect proteins and peptides labelled with molecular tags containing this sequence ([Hilpert \*et al.\* 2001](#)).

---

**References**

1. Evan, G.I. *et al.* (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. [Mol Cell Biol. 5 \(12\): 3610-6.](#)
2. Spandidos, D.A. *et al.* (1987) Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. [Anticancer Res. 7 \(6\): 1299-304.](#)
3. Borodina, I. *et al.* (2010) Display of wasp venom allergens on the cell surface of *Saccharomyces cerevisiae*. [Microb Cell Fact. 9: 74.](#)
4. Groeger, G. *et al.* (2007) Co-operative Cdc42 and Rho signalling mediates ephrinB-triggered endothelial cell retraction. [Biochem J. 404: 23-9.](#)
5. Head, B. *et al.* (2009) Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. [J Cell Biol. 187: 959-66.](#)
6. Hilpert, K. *et al.* (2001) Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. [Protein Eng. 14: 803-6.](#)
7. Krauss, N. *et al.* (2008) The structure of the anti-c-myc antibody 9E10 Fab fragment/epitope peptide complex reveals a novel binding mode dominated by the heavy chain hypervariable loops. [Proteins. 73: 552-65.](#)
8. Gray, P. *et al.* (2010) Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling. [J Immunol. 184: 6359-66.](#)
9. Duriseti, S. *et al.* (2010) Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. [J Biol Chem. 285: 26878-88.](#)
10. Tan, P.H. *et al.* (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. [Blood. 106: 2936-43.](#)
11. Wallace, S.W. *et al.* (2010) Cdc42 regulates apical junction formation in human bronchial epithelial cells through PAK4 and Par6B. [Mol Biol Cell. 21: 2996-3006.](#)
12. Rowshanravan, B. *et al.* (2014) RasGAP mediates neuronal survival in *Drosophila* through direct regulation of Rab5-dependent endocytosis. [J Cell Sci. 127: 2849-61.](#)
13. Taylor K *et al.* (2015) Nanocell targeting using engineered bispecific antibodies. [MAbs. 7 \(1\): 53-65.](#)
14. Elders, R.C. *et al.* (2014) Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells. [Vet Immunol Immunopathol. 159 \(1-2\): 29-40.](#)
15. Sharkey, A.M. *et al.* (2015) Tissue-Specific Education of Decidual NK Cells. [J Immunol. 195 \(7\): 3026-32.](#)

16. McGough, I.J. *et al.* (2014) Identification of molecular heterogeneity in SNX27-retromer-mediated endosome-to-plasma-membrane recycling. [J Cell Sci. 127 \(Pt 22\): 4940-53.](#)
17. Gohlke, S. *et al.* (2017) *In Vitro* and *In Vivo* Studies on the Structural Organization of Chs3 from *Saccharomyces cerevisiae*. [Int J Mol Sci. 18 \(4\): pii: E702.](#)

---

<b>Further Reading</b>	1. Nesbit, C. <i>et al.</i> (1999) MYC oncogenes and human neoplastic disease. <a href="#">Oncogene. 18: 3004-16.</a>
------------------------	---

---

<b>Storage</b>	Store at +4°C or at -20°C if preferred.  This product should be stored undiluted.  Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.  Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
----------------	---

---

<b>Guarantee</b>	18 months from date of despatch.
------------------	----------------------------------

---

<b>Acknowledgements</b>	DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
-------------------------	--

---

<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10040 available at: 10040: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf</a>
--------------------------------------	--

---

<b>Regulatory</b>	For research purposes only
-------------------	----------------------------

---

## Related Products

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

'M336628:181214'

Printed on 15 Mar 2019